|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 F STREET, NW, #480 |
Address2 |
|
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Philip M. Thevenet |
Date | 7/21/2025 7:55:48 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 1: One Big Beautiful Bill Act
H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026
H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14
H.R. 4213: Department of Homeland Security Appropriations Act, 2026
S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
H.R. __: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S. __: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
H.R. __: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
S. __: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Philip |
Thevenet |
|
|
|
Monica |
Cloud |
|
|
|
Liam |
MacDonald |
|
|
|
Harmeet |
Dhillon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 43: Skinny Labels, Big Savings Act
S. 708: RESTORE Patent Rights Act of 2025
S. 1040: Drug Competition Enhancement Act
S. 1041: Affordable Prescriptions for Patients Act
S. 1095: Stop STALLING Act
S. 1096: Preserve Access to Affordable Generics and Biosimilars Act
S. 1097: Interagency Patent Coordination and Improvement Act of 2025
S. 1546: Patent Eligibility Restoration Act of 2025 (PERA)
S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act)
H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act
H.R. 1574: RESTORE Patent Rights Act of 2025
H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA)
H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act)
H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act)
Biopharmaceutical innovation policy issues
Bayh-Dole march-in rights policy issues
Patent thicket policy issues
Patent use codes policy issues
AI patent policy issues
Patent eligibility policy issues
Post-grant proceeding policy issues
Patent submission policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Philip |
Thevenet |
|
|
|
Monica |
Cloud |
|
|
|
Liam |
MacDonald |
|
|
|
Harmeet |
Dhillon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 652: Protecting Patients from Deceptive Drug Ads Act
S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025
S. 864, HELP Copays Act - A bill to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes.
S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry.
S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability)
S. 1302: Increasing Transparency in Generic Drug Applications Act
S. 1414: Expedited Acccess to Biosimilars Act
S. 1784: MAPS Act
S. 1954: Biosimilar Red Tape Elimination Act
H.R. 1: One Big Beautiful Bill Act
H.R. 946: Orphan Cures Act
H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025
H.R. 2214: DRUG Act
H.R. 4132: Prescription Information Modernization Act of 2025
HR 6283: Delinking Revenue from Unfair Gouging (DRUG) Act - bill aimed at reforming practices of Pharmacy Benefit Managers (PBMs) by delinking their revenue from the list price of prescription drugs
Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft)
Biopharmaceutical innovation policy issues
User fee issues
Vaccine policy issues
Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues
Pharmacy Benefit Manager reform and policy issues
Drug cost and pricing policy issues
Drug importation policy issues
Accelerated approval policy issues
FDA policy issues
Competition policy issues
Orphan Drug Act policy issues
Compounding policy issues
Supply chain policy issues
Clinical trial policy issues
340B drug discount program rebate and policy issues
Patient assistance program policy issues
Biosimilar approval and reimbursement policy issues
Drug shortages policy issues
Artificial intelligence policy issues
Executive Order, Delivering Most-Favored Nation Prescription Drug Pricing to American Patients
Executive Order, Lowering Drug Prices by Once Again Putting Americans First
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Philip |
Thevenet |
|
|
|
Monica |
Cloud |
|
|
|
Liam |
MacDonald |
|
|
|
Harmeet |
Dhillon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1: One Big Beautiful Bill Act
Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues
Part D redesign and policy issues including non-interference and rebates policy issues
Part B policy issues
Drug cost and pricing policy issues
Medicare rebate policy issues
Insulin policy issues
Center for Medicare and Medicaid Innovation (CMMI) policy issues
Medicaid waiver policy issues
CMS IPAY Guidance on the Medicare Drug Price Negotiation Program
IPAY and Maximum Fair Prices policy issues
Medicaid rebate policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Philip |
Thevenet |
|
|
|
Monica |
Cloud |
|
|
|
Liam |
MacDonald |
|
|
|
Harmeet |
Dhillon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Executive Order, Delivering Most-Favored Nation Prescription Drug Pricing to American Patients
Tariff policy issues
Biopharmaceutical innovation policy issues
International intellectual property and market access policy issues
Pricing and reimbursement policy issues
Supply chain policy issues
WTO TRIPS waiver policy issues
China outbound investment policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Philip |
Thevenet |
|
|
|
Monica |
Cloud |
|
|
|
Liam |
MacDonald |
|
|
|
Harmeet |
Dhillon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |